| Steven B. Ratoff President & Chief Executive Officer  Mr. Ratoff was appointed by NovaDel's Board in July, 2007, to serve as Interim President and CEO and in 2009 as Interim Chief Financial Officer. Effective January 1, 2010, the company's Board of Directors appointed Mr. Ratoff President and Chief Executive Officer. He continued to serve as Interim Chief Financial Officer until the appointment of Craig Johnson as Chief Financial Officer in June 2010. Mr. Ratoff, a private investor, joined our Board in January 2006 and was elected Chairman of the Board in September 2006. Mr. Ratoff has served as a Venture Partner with ProQuest Investments, a health care venture capital firm, and is a member of the Board of Directors of TorreyPines Therapeutics, Inc. He also served as Chairman of the Board and Interim CEO of CIMA Labs, Inc. prior to its sale to Cephalon, Inc., and as Senior VP and CFO of the Pharmaceutical Group at Bristol-Myers Squibb. Mr. Ratoff brings extensive credentials to the Company from his distinguished career in the pharmaceutical and consumer goods industries. Mr. Ratoff received his B.S. in Business Administration from Boston University and an M.B.A. with Distinction from the University of Michigan. Mr. Ratoff is also a retired Certified Public Accountant. |
| David H. Bergstrom, Ph.D. Senior Vice President & Chief Operating Officer Dr. Bergstrom joined NovaDel in December 2006 as Senior Vice President and Chief Operating Officer. Dr. Bergstrom previously served as Senior Vice President and General Manager of the Pharmaceutical Development business of Cardinal Health, Inc. Dr. Bergstrom previously served as Vice President of Pharmaceutical and Chemical Development at Guilford Pharmaceuticals and also served in senior positions in preclinical development and pharmaceutical and analytical development at Hoechst Marion Roussel, Inc. and Hoechst-Roussel Pharmaceuticals, Inc., both predecessor companies of Sanofi-Aventis Pharmaceuticals, Inc. Prior to that, Dr. Bergstrom worked in pharmaceutical development at CIBA-Geigy Pharmaceuticals, Inc. Dr. Bergstrom received his Ph.D. in Pharmaceutics from the University of Utah, Salt Lake City, his M.S. in Pharmaceutical Chemistry from the University of Michigan, Ann Arbor, and his B.S. in Pharmacy from Ferris State University, Big Rapids, Michigan. |
| Craig A. Johnson Senior Vice President, Chief Financial Officer & Corporate Secretary Mr. Johnson joined NovaDel in June 2010 as Senior Vice President, Chief Financial Officer and Corporate Secretary. Mr. Johnson previously served as Vice President and Chief Financial Officer of TorreyPines Therapeutics from 2004 until its sale to Raptor Pharmaceutical Corp. in September 2009. Following the sale, he served as Vice President of TPTX, Inc., a subsidiary of Raptor Pharmaceutical Corp., until April 2010. From 1994 to 2004, Mr. Johnson was employed by MitoKor, Inc. where he last held the position of Chief Financial Officer and Senior Vice President of Operations. Prior to MitoKor, he served as a senior financial executive for several early-stage technology companies, and he also practiced as a Certified Public Accountant with Price Waterhouse. Currently, Mr. Johnson is as a member of the board of directors of Ardea Biosciences, a publicly-traded biotechnology company, where he serves as the chairman of the audit committee. Mr. Johnson received his BBA in accounting from the University of Michigan and is a certified public accountant. |